Dimensional Fund Advisors LP Grows Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Dimensional Fund Advisors LP raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 8.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 531,190 shares of the specialty pharmaceutical company’s stock after buying an additional 43,523 shares during the period. Dimensional Fund Advisors LP’s holdings in ANI Pharmaceuticals were worth $40,843,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. KBC Group NV purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Hantz Financial Services Inc. boosted its holdings in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the period. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at about $48,000. Finally, State of Wyoming acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 3,313 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at approximately $15,268,698. This represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 55,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the sale, the chief executive officer owned 349,889 shares in the company, valued at $27,140,889.73. The trade was a 13.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 88,029 shares of company stock valued at $6,954,472 over the last ninety days. 8.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Trading Up 1.0%

ANIP opened at $80.06 on Tuesday. The business has a fifty day moving average price of $81.08 and a 200 day moving average price of $79.47. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a 12 month low of $63.67 and a 12 month high of $99.50. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of 20.27 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same quarter last year, the company earned $1.70 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANIP has been the topic of a number of recent research reports. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Guggenheim restated a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group initiated coverage on shares of ANI Pharmaceuticals in a report on Thursday, July 16th. They set a “hold” rating and a $91.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $105.00.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.